State of Alaska Department of Revenue increased its position in shares of Anika Therapeutics Inc. (NASDAQ:ANIK) by 79.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,872 shares of the biotechnology company’s stock after buying an additional 1,272 shares during the period. State of Alaska Department of Revenue’s holdings in Anika Therapeutics were worth $141,000 at the end of the most recent quarter.
Other institutional investors also recently made changes to their positions in the company. Fisher Asset Management LLC raised its position in shares of Anika Therapeutics by 15.3% in the second quarter. Fisher Asset Management LLC now owns 80,904 shares of the biotechnology company’s stock worth $3,992,000 after buying an additional 10,751 shares in the last quarter. Bank of Montreal Can increased its stake in shares of Anika Therapeutics by 12.4% in the second quarter. Bank of Montreal Can now owns 21,190 shares of the biotechnology company’s stock worth $1,046,000 after buying an additional 2,341 shares during the last quarter. Atria Investments LLC increased its stake in shares of Anika Therapeutics by 1.2% in the second quarter. Atria Investments LLC now owns 5,631 shares of the biotechnology company’s stock worth $278,000 after buying an additional 68 shares during the last quarter. Tudor Investment Corp ET AL increased its stake in shares of Anika Therapeutics by 48.1% in the first quarter. Tudor Investment Corp ET AL now owns 25,275 shares of the biotechnology company’s stock worth $1,098,000 after buying an additional 8,206 shares during the last quarter. Finally, Highbridge Capital Management LLC acquired a new stake in shares of Anika Therapeutics during the first quarter worth $843,000. Hedge funds and other institutional investors own 81.27% of the company’s stock.
Shares of Anika Therapeutics Inc. (ANIK) remained flat at $51.57 during midday trading on Thursday. 17,525 shares of the stock were exchanged. The company’s 50-day moving average price is $49.07 and its 200-day moving average price is $47.01. The company has a market capitalization of $755.91 million, a P/E ratio of 22.91 and a beta of 1.69. Anika Therapeutics Inc. has a one year low of $41.38 and a one year high of $53.99.
Anika Therapeutics (NASDAQ:ANIK) last posted its earnings results on Wednesday, July 26th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.44 by $0.32. The company had revenue of $33.50 million during the quarter, compared to analyst estimates of $27.20 million. Anika Therapeutics had a return on equity of 14.88% and a net margin of 30.44%. The company’s revenue for the quarter was up 25.9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.57 EPS. Equities analysts predict that Anika Therapeutics Inc. will post $2.00 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This report was originally reported by Ticker Report and is owned by of Ticker Report. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.tickerreport.com/banking-finance/2800471/anika-therapeutics-inc-nasdaqanik-position-increased-by-state-of-alaska-department-of-revenue.html.
A number of brokerages have weighed in on ANIK. BidaskClub raised shares of Anika Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday. Zacks Investment Research raised shares of Anika Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 2nd.
In other news, CEO Charles H. Sherwood sold 63,799 shares of the business’s stock in a transaction dated Thursday, July 27th. The stock was sold at an average price of $50.79, for a total transaction of $3,240,351.21. Following the completion of the transaction, the chief executive officer now directly owns 174,705 shares in the company, valued at approximately $8,873,266.95. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Charles H. Sherwood sold 14,201 shares of the business’s stock in a transaction dated Wednesday, July 5th. The stock was sold at an average price of $50.03, for a total value of $710,476.03. Following the transaction, the chief executive officer now owns 246,740 shares of the company’s stock, valued at $12,344,402.20. The disclosure for this sale can be found here. Insiders have sold a total of 88,725 shares of company stock valued at $4,459,085 over the last 90 days. Corporate insiders own 6.57% of the company’s stock.
About Anika Therapeutics
Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.
Want to see what other hedge funds are holding ANIK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anika Therapeutics Inc. (NASDAQ:ANIK).
Receive News & Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.